As of September 30, 2025, Extrawell Pharmaceutical Holdings Limited carries a market capitalization of 290.70M, placing it among publicly traded companies globally. Its enterprise value stands at 349.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 290.70M |
| Enterprise Value | 349.71M |
As of September 30, 2025, Extrawell Pharmaceutical Holdings Limited has 2.55B shares outstanding.
| Shares Outstanding | 2.55B |
These figures are as of September 30, 2025.
| PB Ratio | 0.33 |
| P/TBV Ratio | 0.33 |
As of September 30, 2025, Extrawell Pharmaceutical Holdings Limited maintains a current ratio of 13.06, meaning it holds 13.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.06 |
| Quick Ratio | 1.92 |
| Debt / Equity | 17.09 |
These figures cover the twelve months ended September 30, 2025.
| Employee Count | 163.00 |
As of the close on November 17, 2026, Extrawell Pharmaceutical Holdings Limited's stock has declined approximately 30.38% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.07.
| 52-Week Price Change | -30.38% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.07 |
As of September 30, 2025, Extrawell Pharmaceutical Holdings Limited holds 94.39M in cash and equivalents against 152.68M in total debt, resulting in a net debt position of 58.83M. Total book value stands at 892.64M, with working capital of 592.34M providing operational flexibility.
| Cash & Cash Equivalents | 94.39M |
| Total Debt | 152.68M |
| Net Debt | 58.83M |
| Equity (Book Value) | 892.64M |
| Book Value Per Share | 0.35 |
| Working Capital | 592.34M |
Extrawell Pharmaceutical Holdings Limited's most recent stock split took place on February 17, 2000 with a 1:10 split ratio.
| Last Split Date | 2/17/2000 |
| Split Ratio | 1:10 |
Already premium?